Stifel Adjusts Bio-Techne's Price Target to $75 From $65
Scotiabank Maintains Bio-Techne(TECH.US) With Buy Rating, Raises Target Price to $88
Benchmark Co. Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $95
Bio-Techne Analyst Ratings
RBC Capital Maintains Bio-Techne(TECH.US) With Hold Rating, Raises Target Price to $79
Baird Maintains Bio-Techne(TECH.US) With Buy Rating, Raises Target Price to $84
KeyBanc Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $80
RBC Capital Maintains Bio-Techne(TECH.US) With Hold Rating, Raises Target Price to $77
Bio-Techne (TECH) Gets a Hold From RBC Capital
Baird Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $82
Optimistic Growth and Improved Financial Outlook for Bio-Techne: A Buy Recommendation
Scotiabank Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $83
Scotiabank Reaffirms Their Buy Rating on Bio-Techne (TECH)
Bio-Techne Price Target Maintained With a $95.00/Share by Benchmark
Bio-Techne Analyst Ratings
Benchmark Co. Maintains Bio-Techne(TECH.US) With Buy Rating, Maintains Target Price $95
Benchmark Co. Remains a Buy on Bio-Techne (TECH)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Pediatrix Medical Group (MD) and Arcus Biosciences (RCUS)
Buy Rating Affirmed for Bio-Techne on Strong Consumables Foundation and Market Growth Potential
RBC Capital Maintains Sector Perform on Bio-Techne, Lowers Price Target to $70
No Data
No Data